Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Combination Talazoparib - Carboplatin for Recurrent High-grade Glioma With DNA Damage Repair Deficiency (DDRd)

NCT04740190 is registered in ClinicalTrials.gov with The University of Hong Kong as lead sponsor.

NCT NCT04740190
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04740190 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Combination Talazoparib - Carboplatin for Recurrent High-grade Glioma With DNA Damage Repair Deficiency (DDRd)
Lead sponsor
The University of Hong Kong
Phase
Phase 2
Overall status
Completed
Start date
January 1, 2021
Completion date
December 14, 2023
Enrollment
33 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

idh mutation, poly adp ribose polymerase (parp) inhibitor, pten gene inactivation, recurrent glioblastoma, recurrent glioma